encorafenib + infigratinib

Encorafenib + infigratinib is a combination of two small molecule kinase inhibitors, **encorafenib** and **infigratinib**. Encorafenib is a potent inhibitor of the BRAF serine/threonine kinase, particularly effective against tumors with BRAF V600 mutations, and is primarily used in targeted therapy for unresectable or metastatic melanoma, metastatic colorectal cancer, and metastatic non-small cell lung cancer with BRAF V600E mutations[^2][^5][^6]. Infigratinib is a selective inhibitor of fibroblast growth factor receptors (FGFR) types 1–3, mainly investigated for the treatment of cancers with FGFR genetic alterations, such as cholangiocarcinoma and urothelial carcinoma. There is no evidence in the provided literature supporting the clinical development or use of the specific combination "encorafenib + infigratinib." Clinical combinations with encorafenib have involved agents such as binimetinib (a MEK inhibitor) or cetuximab (an EGFR inhibitor), not infigratinib. The mechanisms of action, pharmacological rationale, or current development status of the exact "encorafenib + infigratinib" combination are not described in any approved labeling or publicly available clinical trial, suggesting this combination is **not a recognized or approved clinical product**.